236 related articles for article (PubMed ID: 26846855)
1. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.
Heir P; Srikumar T; Bikopoulos G; Bunda S; Poon BP; Lee JE; Raught B; Ohh M
J Biol Chem; 2016 Apr; 291(14):7357-72. PubMed ID: 26846855
[TBL] [Abstract][Full Text] [Related]
2. Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL).
Heir P; Ohh M
Methods Mol Biol; 2016; 1458():87-94. PubMed ID: 27581016
[TBL] [Abstract][Full Text] [Related]
3. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
4. HIF-1α Hydroxyprolines Modulate Oxygen-Dependent Protein Stability Via Single VHL Interface With Comparable Effect on Ubiquitination Rate.
He W; Batty-Stuart S; Lee JE; Ohh M
J Mol Biol; 2021 Nov; 433(22):167244. PubMed ID: 34537235
[TBL] [Abstract][Full Text] [Related]
5. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
[TBL] [Abstract][Full Text] [Related]
6. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
7. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
9. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
10. The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.
Kaelin WG
Trans Am Clin Climatol Assoc; 2017; 128():298-307. PubMed ID: 28790514
[TBL] [Abstract][Full Text] [Related]
11. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis.
Semenza GL
Blood; 2009 Sep; 114(10):2015-9. PubMed ID: 19494350
[TBL] [Abstract][Full Text] [Related]
12. CUL2-mediated clearance of misfolded TDP-43 is paradoxically affected by VHL in oligodendrocytes in ALS.
Uchida T; Tamaki Y; Ayaki T; Shodai A; Kaji S; Morimura T; Banno Y; Nishitsuji K; Sakashita N; Maki T; Yamashita H; Ito H; Takahashi R; Urushitani M
Sci Rep; 2016 Jan; 6():19118. PubMed ID: 26751167
[TBL] [Abstract][Full Text] [Related]
13. USP9X destabilizes pVHL and promotes cell proliferation.
Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
[TBL] [Abstract][Full Text] [Related]
14. VHL type 2B mutations retain VBC complex form and function.
Hacker KE; Lee CM; Rathmell WK
PLoS One; 2008; 3(11):e3801. PubMed ID: 19030229
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets from VHL studies into the oxygen-sensing pathway.
Maynard MA; Ohh M
Curr Cancer Drug Targets; 2005 Aug; 5(5):345-56. PubMed ID: 16101382
[TBL] [Abstract][Full Text] [Related]
16. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
17. The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1.
Lai Y; Song M; Hakala K; Weintraub ST; Shiio Y
Arch Biochem Biophys; 2012 Feb; 518(2):103-10. PubMed ID: 22234250
[TBL] [Abstract][Full Text] [Related]
18. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
19. Systemic VHL gene functions and the VHL disease.
Bader HL; Hsu T
FEBS Lett; 2012 Jun; 586(11):1562-9. PubMed ID: 22673568
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
